I. L. Ray-Coquard

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, C. Sessa, Andreas du Bois et al. · International Journal of Gynecological Cancer · 2019 · 385 citations · Full text

Borderline Tumours, Tumoral Pathology, Medicine +9

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier et al. · The Lancet Oncology · 2020 · 306 citations · Full text

Surgical Oncology, Advanced Ewing Sarcoma, Medicine +5

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 144 citations

Carboplatin-based Doublet, Medicine, Metronomic Therapy +7

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

Sant P. Chawla, Jean‐Yves Blay, I. L. Ray-Coquard et al. · Journal of Clinical Oncology · 2011 · 77 citations

Mtor Inhibitor Ridaforolimus, Advanced Sarcoma Patients, Pfs Events +15

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

Éric Pujade-Lauraine, Keiichi Fujiwara, JA Ledermann et al. · Gynecologic Oncology · 2019 · 61 citations

Biomarker Analysis, Medicine, Gynecology +8